What clinical outcomes did Polivy trials track?
Polivy (polatuzumab vedotin) clinical studies measured outcomes using a mix of response-based endpoints and measures of how long patients benefited. The most commonly reported endpoints included tumor response (such as overall response), duration of that response (such as duration of response), and survival outcomes (such as progression-free survival and overall survival), depending on the specific study design and treatment setting. [1]
How were response outcomes measured (e.g., overall response)?
Response outcomes in Polivy trials were typically measured by imaging-based tumor assessments using standard oncology criteria for tumor burden and response classification. Patients’ tumor measurements from scans were used to determine whether the cancer responded, and responses were then categorized into response categories that feed into endpoints like overall response and duration of response. [1]
How were “how long patients benefited” outcomes measured?
Endpoints that reflect time—such as progression-free survival and overall survival—were measured by following patients from treatment start until a defined clinical event occurred, such as disease progression for progression-free survival, or death for overall survival. Investigators determined the event dates using prespecified rules in the trial protocol, often combining scheduled assessments with investigator assessments of progression and death reporting. [1]
How were safety and tolerability outcomes measured alongside efficacy?
Trials also measured clinical outcomes related to side effects using standard adverse-event tracking (recording and grading treatment-emergent events). While this is not an “efficacy” endpoint, safety outcomes are part of how clinical outcomes are measured in Polivy studies. [1]
Does the measurement method vary by trial or indication?
Yes. Polivy is studied across different combinations and patient populations, so the exact endpoints and how they were operationalized can vary by study (for example, which response criteria were used and the specific timing of scan assessments). The core approach—imaging-based tumor assessments for response and time-to-event tracking for survival-type endpoints—remains consistent across oncology trials, but the detailed endpoint definitions and timing are study-specific. [1]
Sources
[1] https://clinicaltrials.gov